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Abstract
Background:  In asthma interleukin (IL)-13 is increased in the airway compared with non-
asthmatic eosinophilic bronchitis. Whether this differential expression is specific to the airway or
is more generalised is uncertain.
Methods: We sought to examine IL-13 expression in peripheral blood T-cells and eosinophils in
asthma and non-asthmatic eosinophilic bronchitis. Peripheral blood CD3+ cell and eosinophil
intracellular IL-13 expression from subjects with asthma, non-asthmatic eosinophilic bronchitis and
healthy controls was assessed. The effect of priming by asthmatic serum on the release of IL-13 by
peripheral blood mononuclear cells from healthy subjects was examined and the serum from these
subjects was analysed for a range of chemokines and cytokines.
Results: The median (IQR)% intracellular IL-13 expression by CD3+ cells was increased in asthma
[5.3 (2.7–9.8)%; n = 12] compared to non-asthmatic eosinophilic bronchitis [1.1 (0.5–3)%; n = 7]
and healthy controls [1.7 (0.2–3%); n = 9] (p = 0.02), but was not significantly different in
eosinophils across the groups. IL-13 released from healthy peripheral blood mononuclear cells (n
= 10) was increased by asthmatic serum [117 (47.8–198)pg/ml] compared to control [78.5 (42.6–
128)pg/ml; p = 0.02), but was not affected by non-asthmatic serum.
Conclusion: Our findings support the view that IL-13 expression is increased in peripheral blood-
derived T cells in asthma and that asthmatic serum up-regulates IL-13 release from healthy
peripheral blood mononuclear cells.
Background
Asthma is characterised by the presence of variable airflow
obstruction, airway hyper-responsiveness (AHR), and an
airway inflammatory response often characterised by Th2-
mediated eosinophilic airway inflammation [1] with mast
cell infiltration of the airway smooth muscle (ASM) bun-
dle[2]. The Th2 cytokine interleukin (IL)-13 has been
implicated in the pathogenesis of asthma[3]. Its central
role in the asthma paradigm is supported by human stud-
ies that have reported increased IL-13 mRNA expression
in bronchial biopsies from subjects with moderate
asthma[4,5] and from sputum cells from corticosteroid
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naïve and inhaled corticosteroid treated asthmatics[6]. In
addition, following allergen challenge in mild asthmatics
bronchoalveolar lavage IL-13 concentration was upregu-
lated[7]. This association between IL-13 and asthma in
humans is supported by animal models[8]. T-lymphocyte
deficient mice have shown exogenous addition of IL-13
promotes AHR and airway inflammation, while neutrali-
sation of IL-13 in murine models can resolve these fea-
tures[9].
Importantly comparisons between asthma and non-asth-
matic eosinophilic bronchitis (EB), a common cause of
chronic cough[10] in which disordered airway physiology
is not a feature, have been informative about the key
immunopathological features of asthma. Over expression
of IL-13 in sputum [11-13], bronchial submucosa[11,12]
and co-localisation to mast cells in the ASM-bundle[14]
are features of asthma that are not shared by EB and have
therefore further supported its role in the pathogenesis of
AHR. Whether this differential IL-13 expression is specific
to the airway or is a generalised phenomenon present in
peripheral blood cells is uncertain.
We hypothesised that IL-13 expression is upregulated in
peripheral blood T-cells and eosinophils in asthma com-
pared to EB and healthy controls. We have further consid-
ered the possibility that asthmatic serum contains a pro-




Subjects with asthma (n = 24) and EB (n = 7) and healthy
volunteers (n = 16) were recruited from Glenfield Hospi-
tal outpatients, staff and by local advertising. All subjects
were non-smokers with a smoking history of < 10 pack
years; had been free of exacerbations and on stable treat-
ment for 8 weeks prior to entry into the study. EB was
defined according to the American College Of Chest Phy-
sicians (ACCP) criteria[15]. Asthma was defined by one or
more of the following objective criteria: significant bron-
chodilator reversibility of > 200 mls, a provocation con-
centration of methacholine causing a 20% fall in FEV1
(PC20) of less than 8 mg/ml or a peak flow amplitude %
mean over 2 weeks of more than 20%. Severity was classi-
fied using the current global initiative for asthma (GINA)
treatment steps[16]. Normal subjects had no history of
respiratory disease and normal spirometry. The Leicester-
shire ethics committee approved the study and all patients
gave their written informed consent.
Protocol and clinical characterisation
Subjects underwent spirometry, allergen skin prick tests
for Dermatophagoides pteronyssinus, dog, cat and grass pol-
len, measurement of exhaled nitric oxide (eNO) concen-
tration (measured at 50 mls/s NIOX; Aerocrine,
Stockholm, Sweden), a methacholine inhalation test[17]
and sputum induction[18].
Isolation of peripheral blood mononuclear cells (PBMC) 
and eosinophils
Mononuclear cells and eosinophils were isolated from
peripheral blood. Briefly, 100 mls of heparinised periph-
eral blood was venesected from a subgroup of the patients
with asthma (n = 12), EB (n = 7) and healthy controls (n
= 9). After an initial step of Dextran red cell sedimenta-
tion, the plasma layer was removed and after centrifuga-
tion the cell pellet was resuspended over Histopaque 1077
(Sigma, Poole, Dorset, UK). After further centrifugation
the mononuclear cell interface was collected and washed
twice with phosphate buffered saline. For eosinophil sep-
aration the remaining pellet after histopaque centrifuga-
tion underwent red cell lysis followed by negative
immunomagnetic selection using anti-CD16 coated
immunomagnetic beads. There were insufficient eosi-
nophils isolated to undertake further experiments from 3
healthy controls and 1 subject with EB. Cell purity and
viability was assessed and was > 95% in all subjects. Fol-
lowing purification PBMC and eosinophils were cultured
at 1 × 106 cells/ml in RPMI 1640 medium supplemented
with 10% fetal calf serum and either left unstimulated in
the presence of brefeldin or stimulated with phorpbol
myristate acetate (PMA) [5 ng/ml; Sigma Chemical Co,
UK] and calcium ionophore [250 ng/ml; Sigma, UK] in
the presence of the fungal protein brefeldin [10 μg/ml] for
4 h at 37°C.
Intracellular Flow cytometry for IL-13
The cells were fixed in 4% paraformaldehyde (Sigma, UK)
and stored overnight at 4°C in PBS, 0.5% BSA. The fol-
lowing day the cells were washed and incubated with
CD3-RPE (mononuclear cells only) (BD biosciences, UK)
permeabilised in 4% paraformaldehyde, 0.1% saponin
(Sigma, UK) for 15 min on ice and labelled with IL-13-
FITC (BD biosciences, UK) or isotype controls and ana-
lysed by two-colour flow-cytometry as described previ-
ously[19].
Stimulation of healthy PBMC with asthmatic serum
PBMC from 10 healthy controls, including 3 subjects that
had participated in the first part of this study, were stimu-
lated with pooled serum from asthmatic subjects and
PBMC from 4 of these subjects were stimulated with
pooled serum from non-asthmatics.
PBMC stimulation was carried out in 24-well cell culture
plates in duplicates in the presence and absence of 0.1, 1
and 10% human serum. IL-17E has been implicated to
promote IL-13 release from PBMC and may be an impor-
tant mediator in the asthmatic serum. Therefore the serumBMC Pulmonary Medicine 2009, 9:34 http://www.biomedcentral.com/1471-2466/9/34
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stimulation was undertaken with and without recom-
binant human IL-17E (100 ng/ml) and or IL-17E neutral-
ising antibody (20 μg/ml) (R&D Systems, Abingdon,
Oxford, UK). 500 μl of PBMC suspension was added to
each well equating to 2 × 106 PBMC/well. Finally, 250 μl
of either DMEM alone, or DMEM containing 4 × final
concentration (final concentration was 20 ng/ml) of PMA
(Sigma, UK) was added to the cells. The cells were incu-
bated for 16 h at 37°C in a humidified atmosphere
flushed with 5% CO2. Following the incubation, PBMC
were decanted into 1.5 ml Eppendorf® tubes and centri-
fuged at 400 × g for 5 min. The supernatants were
removed and stored at -20°C for analysis.
IL-13 was measured using a sandwich ELISA (Bender
MedSystems, UK). The limit of detection of the ELISA was
1.56 pg/ml. The IL-13 concentration in the pooled asth-
matic and non-asthmatic serum was subtracted from the
concentration of IL-13 released by stimulated PBMC
primed with serum.
Mesoscale analysis of serum from asthmatics and healthy 
controls
The concentration of a panel of cytokines and chemokines
were measured in serum from the 10 healthy subjects that
had participated in asthmatic serum-stimulated PBMC
experiments and 12 asthmatics using the mesoscale dis-
covery system. This assay uses electrochemiluminescence
detection and pattern arrays (Mesoscale Discovery, Gaith-
ersburg, Maryland, USA). The panel included the
cytokines (IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-8 (CXCL8), IL-
10, IL-12p70, IL-13, TNF-α) and chemokines (CCL11,
CCL4, CCL26, CCL17, CXCL10, CCL2, CCL22, CCL13).
The limits of detection of the mesoscale system were,
[CCL2; 1 pg/ml], [CCL4; 20 pg/ml], [CCL11; 10 pg/ml],
[CCL13; 100 pg/ml], [CCL17; 50 pg/ml], [CCL22; 150 pg/
ml], [CCL26; 200 pg/ml], [CXCL8; 1 pg/ml], and
[CXCL10; 200 pg/ml], all other limits of detection were 1
pg/ml.
Statistical analysis
Subject characteristics were described using descriptive
statistics. Intracellular IL-13 was expressed as a percentage
above isotype control and expressed as the median and
interquartile range (IQR). Comparison across the three
groups was performed using a Kruskal-Wallis one-way
analysis of variance with Dunns post test for inter-group
comparisons. Paired data were analysed using the Wil-
coxon matched pairs t-test.
Results
Baseline clinical characteristics are shown in Table 1. The
subjects with severe asthma and non-asthmatic eosi-
nophilic bronchitis were older than those with mild
asthma or healthy controls. Eosinophilic inflammation
was a feature of subjects with asthma and non-asthmatic
eosinophilic bronchitis, whereas airway hyper-respon-
siveness was reserved to those with asthma.
IL-13 expression is increased in PBMC but not eosinophils 
in asthma compared to EB
Intracellular expression of IL-13 was significantly
increased at baseline in peripheral blood CD3+ T cells in
asthma compared to patients with EB and healthy con-
trols (figures 1a &1b). The median (IQR) % intracellular
expression was 5.3(2.7–9.8)% asthma, 1.3(0.2–2.1)% EB
and 1.1(0.2–3%) controls (p = 0.007 Kruskal-Wallis; p <
0.05 Dunn's post-hoc test asthma versus EB/Controls).




(GINA 1 = 6, GINA 2–3 = 6)
Asthma Severe
(GINA 4 = 6, GINA 5 = 6)
Eosinophilic Bronchitis
(n = 7)
Age (yrs)~ 32.2 (2.3) 37.3 (3.7) 51.0 (4.3)* 53.6 (6.2)*
Sex M:F 7:9 7:5 4:8 6:1
Atopy (%) 46 83** 67** 43
Disease Duration (yrs) N/A 22.0 (3.8)** 30.4 (4.9)** 8.4(1.8)
BDP Equivalent (mcg) N/A 355 (132) 1633 (175) 1149(420)
Oral Prednisolone
(mg/24 hrs)
N/A N/A 5.6 (2.0) 0
ENO (50)
(Ppb) #
18 [9–37] 28 [19–46] 19 [14–25] 34 [18–64]
PC20 (mg/ml)# >16 1.4 [0.4–4.9]** 0.45 [0.1–1.7]** >16
FEV1 % predicted~ 109 (3.3) 90 (8.7) 78 (6.0)* 95.7(5.6)
FEV1/FVC~ 86.3(1.7) 79 (3.4) 72 (3.5)* 80.0(4.4)
Induced sputum
Eosinophils (%)# 0.7 [0.2–2.7] 2.2 [0.4–13.0]* 1.9 [0.8–4.6]* 4.6 [1.3–16.5]*
Neutrophils (%)~ 43 (12.6) 46 (9.9) 66.5 (7.1) 43.5(5.6)
~ mean (SEM), # geometric mean (95% confidence interval), N/A not applicable
*p < 0.05 vs. control, **p < 0.05 vs. control and/or EBBMC Pulmonary Medicine 2009, 9:34 http://www.biomedcentral.com/1471-2466/9/34
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Intracellular expression of IL-13 in CD3+ T cells Figure 1
Intracellular expression of IL-13 in CD3+ T cells. 1a: Representative histograms and dot plot of the percentage of CD3+ 
T cells expressing IL-13 in asthma, EB and healthy controls at baseline. Solid peak (isotype control), solid line (IL-13 FITC con-
jugate). 1b: Increased % expression by CD3 T cells of IL-13 in asthma at baseline compared to patients with EB and healthy 
subjects. *p < 0.05 (asthma subdivided into those with mild-moderate disease closed circles and severe asthma open circles). 
1c: Upregulation of CD3+ T cell and eosinophil IL-13 expression in asthma after mitogen stimulation. Fold increase in IL-13 flu-
orescence compared to isotype control before and after mitogen stimulation.BMC Pulmonary Medicine 2009, 9:34 http://www.biomedcentral.com/1471-2466/9/34
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Following stimulation there was a significant increase in
the expression of IL-13 in CD3+ T cells in asthma (p =
0.02), but not in patients with EB or healthy controls (fig-
ure 1c). In asthma, there was no correlation between the
T-cell intracellular IL-13 expression and the sputum eosi-
nophil count or AHR (r = 0.17; p = 0.69 and r = 0.26; p =
0.46 respectively) and no difference between the intensity
of expression in those with or without atopy (p = 0.11).
The median (IQR) baseline % intracellular expression of
IL-13 in eosinophils was not significantly different
between subjects with asthma 7.2 (0–16.7)%, EB 12.1 (0–
22.6)%, or healthy controls 1.4 (0–3.3)% (p = 0.2 Kruskal
Wallis; figure 1b). There was no significant increase in IL-
13 expression by eosinophils following stimulation (fig-
ure 1c).
Stimulation of PBMC from healthy subjects with pooled 
asthmatic serum leads to increased IL-13 release that is not 
mediated by IL-17E
The median (interquartile range) IL-13 release from
PBMC stimulated with PMA was 78.5(42.6–128) pg/ml].
This was significantly increased after stimulation with 1%
asthmatic serum (117 [47.8–198] pg/ml; p = 0.027; mean
[SEM]% increase 36 [27]%); with a non-significant trend
towards an increase with 10% serum (90.2 [47.7–278.8]
pg/ml; p = 0.08; 58 [32]% increase), but not 0.1% serum
(85 [48.9–197.2] pg/ml; p = 0.4; 70 [43]% increase). The
PMA-mediated IL-13 release by PBMC was not affected by
stimulation with serum from non-asthmatic individuals
(figure 2).
IL-13 release was not altered by recombinant IL-17E
[79.5(62.6–170.2) pg/ml]; p = 0.2 or IL-17E neutralising
antibody (data not shown).
Systemic inflammation in severe asthma
We found that the following chemokines were signifi-
cantly up-regulated in the serum in asthma compared to
healthy subjects CCL2, CCL4, CCL11 and CCL13 (p <
0.05). In contrast we did not find increased cytokine
expression in asthmatic serum (Figure 3).
Discussion
We have shown that in asthma IL-13 expression is
increased in peripheral blood T cells, but not eosinophils
compared to subjects with EB or healthy subjects. In addi-
tion IL-13 released by PBMC from healthy controls was
increased by asthmatic serum. This suggests that the
increased IL-13 expression in asthma may be mediated by
a hitherto undetermined pro-inflammatory stimulus in
asthmatic serum. This stimulus is not IL-17E, and we were
unable to find a plausible candidate mediator with mes-
oscale analysis of a range of cytokines and chemokines.
We report here for the first time differential expression of
intracellular IL-13 in peripheral blood T-cells from asth-
matics compared to subjects with EB and healthy controls.
This supports our hypothesis that increased IL-13 expres-
sion in asthma is not reserved to the airway but is also
present in peripheral blood inflammatory cells. Our find-
ings are consistent with a previous study by Park et al[20],
in which IL-13 secretion by PBMC was increased in
asthma compared to EB and healthy controls. In addition
we have shown for the first time that IL-13 expression in
eosinophils was not different between subjects with
asthma and EB, although there was a non-significant
trend towards increased expression in eosinophils in the
disease groups compared to controls. This suggests that
the observed up-regulation of the IL-13 axis by airway
eosinophils in asthma [11-13] may be influenced by the
local microenvironment.
Importantly, we have demonstrated that serum from asth-
matics but not from non-asthmatics can promote
increased IL-13 release from healthy PBMC suggesting
that asthmatic serum contains an activator of the IL-13
pathway. We investigated the role of IL-17E a known pro-
inflammatory primer for IL-13 release as a potential can-
didate[21], but our findings do not support a role for IL-
17E as a primer for IL-13 release in peripheral blood. In
addition we were unable to identify a potential pro-
inflammatory candidate in serum across a range of chem-
okines and cytokines assessed by mesoscale analysis.
Asthmatic serum increases IL-13 release from healthy T Cells Figure 2
Asthmatic serum increases IL-13 release from 
healthy T Cells. Mean (SEM) percentage increase in IL-13 
release by PBMC from healthy donors after stimulation with 
mitogen in the presence of 0.1–10% pooled serum from sub-
jects with asthma and non-asthmatic controls. Closed bars 
PBMC (n = 10) stimulated with asthmatic serum, open bars 
PBMC (n = 4) stimulated with non-asthmatic serum.BMC Pulmonary Medicine 2009, 9:34 http://www.biomedcentral.com/1471-2466/9/34
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Therefore further work is required to assess the potential
role of systemic inflammation in mediating up-regulated
Th2 cytokine expression in asthma.
Our findings further strengthen the argument for IL-13
being a key mediator in the pathogenesis of AHR in
asthma. IL-13 may promote AHR by a variety of diverse
mechanisms. In vitro IL-13, but not IL-4, has been shown
to attenuate ASM relaxation to β-agonists[22] and aug-
ment contractility to acetylcholine[23] suggesting that IL-
13 may induce AHR by directly activating ASM. Indirectly
IL-13 may modulate AHR by its effects on airway smooth
muscle proliferation[24] and interactions with the airway
epithelium[25]. In contrast to Park et al [20], we were una-
ble to demonstrate a correlation between AHR and T-cell
IL-13 expression suggesting that the relationship between
the intensity of IL-13 expression and AHR is complex as
we have previously described in severe asthma[12].
One potential criticism of our study is its cross-sectional
design as this does limit our interpretation of the possible
effects of corticosteroid therapy and the longitudinal vari-
ability of IL-13 expression in peripheral blood cells. How-
ever, we are confident that we have established key
differences in IL-13 expression between asthma and EB by
peripheral blood T-cells supporting the view that the dif-
ferences observed in the airway and also present systemi-
cally. Further work is required to explore the mechanisms
driving this differential IL-13 expression.
Conclusion
In conclusion we have found that IL-13 expression is
increased in peripheral blood T-cells in asthma compared
to EB and healthy subjects, which in part may be due to a
pro-inflammatory stimulus in asthmatic serum. This fur-
ther supports the role of IL-13 in asthma.
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